| Name | Title | Contact Details |
|---|
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.
Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
GenVec is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.